1
Clinical Trials associated with IDH1 peptide vaccine (University Hospital Heidelberg)Targeting IDH1R132H in WHO Grade III-IV IDH1R132H-mutated Gliomas by a Peptide Vaccine - a Phase I Safety, Tolerability and Immunogenicity Multicenter Trial (NOA-16)
The NOA-16 trial is the first-in-man trial of the IDH1 (isocitrate dehydrogenase type 1) peptide vaccine targeting the IDH1R132H mutation (amino acid exchange from arginine to glutamine at position 132 of IDH1). The aim of this trial is to evaluate the safety and tolerability of and immune response to the IDH1 peptide vaccine in patients with IDH1R132H-mutated, WHO grade III-IV gliomas.
100 Clinical Results associated with IDH1 peptide vaccine (University Hospital Heidelberg)
100 Translational Medicine associated with IDH1 peptide vaccine (University Hospital Heidelberg)
100 Patents (Medical) associated with IDH1 peptide vaccine (University Hospital Heidelberg)
100 Deals associated with IDH1 peptide vaccine (University Hospital Heidelberg)